Effects of mutations in the post-translational modification sites on the trafficking of hyaluronan synthase 2 (HAS2).


Journal

Matrix biology : journal of the International Society for Matrix Biology
ISSN: 1569-1802
Titre abrégé: Matrix Biol
Pays: Netherlands
ID NLM: 9432592

Informations de publication

Date de publication:
07 2019
Historique:
received: 29 06 2018
revised: 22 10 2018
accepted: 22 10 2018
pubmed: 6 11 2018
medline: 4 12 2019
entrez: 6 11 2018
Statut: ppublish

Résumé

Vesicular trafficking of hyaluronan synthases (HAS1-3) from endoplasmic reticulum (ER) through Golgi to plasma membrane (PM), and either back to endosomes and lysosomes, or out into extracellular vesicles, is important for their activities. We studied how post-translational modifications affect the trafficking of HAS2 by mutagenesis of the sites of ubiquitination (K190R), phosphorylation (T110A) and O-GlcNAcylation (S221A), using Dendra2- and EGFP-HAS2 transfected into COS1 cells. Confocal microscopy showed HAS2 wild type (wt) and its K190R and S221A mutants in ER, Golgi and extracellular vesicles, while the T110A mutant remained mostly in the ER. HA synthesis was reduced by S221A, while completely blocked by K190R and T110A. Cell-surface biotinylation indicated that T110A was absent from PM, while S221A was close to the level of wt, and K190R was increased in PM. TIRF microscopy analysis gave similar results. Rab10 silencing increased HA secretion by HAS2, likely by inhibiting endocytosis of the enzyme from PM, as reported before for HAS3. Green-to-red photo-conversion of Dendra2-HAS2 constructs suggested slower decay of K190R and S221A than HAS2 wt, while T110A was barely degraded at all. S221D and S221E, the phosphomimetic mutants of this site, decayed faster and blocked hyaluronan synthesis, suggesting alternative O-GlcNAc/-PO

Identifiants

pubmed: 30394292
pii: S0945-053X(18)30278-6
doi: 10.1016/j.matbio.2018.10.004
pii:
doi:

Substances chimiques

HAS2 protein, human EC 2.4.1.212
Hyaluronan Synthases EC 2.4.1.212

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

85-103

Informations de copyright

Copyright © 2018. Published by Elsevier B.V.

Auteurs

R M Melero-Fernandez de Mera (RM)

Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland. Electronic address: raquel.melerofernandez@ceu.es.

U T Arasu (UT)

Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland.

R Kärnä (R)

Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland.

S Oikari (S)

Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland.

K Rilla (K)

Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland.

D Vigetti (D)

Department of Medicine and Surgery, University of Insubria, Varese, Italy.

A Passi (A)

Department of Medicine and Surgery, University of Insubria, Varese, Italy.

P Heldin (P)

Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.

M I Tammi (MI)

Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland.

A J Deen (AJ)

Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland; A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH